scholarly journals Allergic rhinitis and allergic conjunctivitis: one disease - two clinical forms

2015 ◽  
Vol 12 (3) ◽  
pp. 22-29
Author(s):  
O M Kurbacheva ◽  
K S Pavlova

This paper has summarized some questions of allergic rhinitis and allergic conjunctivitis classification, diagnosis and treatment. The rapid onset of effect, high efficiency and low bioavailability determine the feasibility of local antihistamines to treat AR and AK, especially in case of a local failure.

Allergy ◽  
2021 ◽  
Author(s):  
Ibon Eguiluz‐Gracia ◽  
Almudena Testera‐Montes ◽  
Carmen Rondon

The Analyst ◽  
2022 ◽  
Author(s):  
Leilei Meng ◽  
Rui Hu ◽  
Jinping Chen ◽  
Tianjun Yu ◽  
Xiaopin Cai ◽  
...  

Quantification of phenylalanine in clinic samples is essential to diagnosis and treatment of phenylketonuria in neonates. In this report, an enzyme cascade strategy was proposed and a high efficiency fluorescence...


2021 ◽  
Vol 18 (2) ◽  
pp. 66-76
Author(s):  
Alexander V. Emelyanov ◽  
Galina R. Sergeeva ◽  
Evgenia V. Leshenkova

The second generation of H1-antihistamines is approved for the stepwise treatment of seasonal and perennial allergic rhinitis in adults and children by international and national guidelines. They reduce the severity of nasal and ocular symptoms of rhinitis and improve the quality of life of patients. Bilastine, a piperidine derivative, is a novel H1-antihistamine. It has a potent and selective effect on H1- receptors and a rapid onset and long duration of action and substantially reduces nasal and ocular symptoms of seasonal and perennial allergic rhinitis. Bilastine has no clinically substantial hepatic metabolism and has a high safety profile: it has no sedative effect, does not affect cognitive functions, has no cardiotoxic effects, and does not interact with alcohol and benzodiazepines in normal and high doses. Tachyphylaxis does not develop despite long-term (up to 1 year) use. Bilastine is registered for clinical use in adults and children aged 12 years. The results of clinical and experimental studies have demonstrated that bilastine has many of the features of modern H1-antihistamines recommended by international guidelines.


2017 ◽  
Vol 16 (2) ◽  

Allergic rhinitis is one of the most common disease. The article presents the main aspects of the etiology, pathogenesis, diagnosis and treatment of this nosology.


2009 ◽  
pp. 537-543
Author(s):  
Matthew A. Dahlgren ◽  
Jay H. Krachmer

2019 ◽  
Vol 123 (5) ◽  
pp. S57
Author(s):  
P. Zieglmayer ◽  
P. Lemell ◽  
N. Unger- Manhart ◽  
A. Goessl ◽  
R. Zieglmayer ◽  
...  

Immunotherapy ◽  
2019 ◽  
Vol 11 (16) ◽  
pp. 1387-1397
Author(s):  
Alson Wai-ming Chan ◽  
Wing Pan Luk ◽  
Ling Hiu Fung ◽  
Tak Hong Lee

Aim: We investigated sublingual immunotherapy for mite-induced allergic rhinitis and its comorbid allergic conditions. Patients & methods: A prospective case-controlled study of 120 patients (case = 80, control = 40) over 12 months. Results: There was 53.6% reduction in total rhinitis symptom score (p < 0.0001), but not in controls (-7.3%, p = 0.99). The total symptom scores for concurrent asthma decreased from 17.79 to 8.8 (p < 0.0001); for allergic conjunctivitis from 20.89 to 10.0 (p = 0.0002); for atopic dermatitis from 46.40 to 29.38 (p = 0.0004) and 74.6% of patients weaned off nasal topical steroids. The treatment-related adverse reactions were mild and self-limiting. Conclusion: Though sublingual immunotherapy may be more expensive than conventional treatments, it was an adjunctive therapy that improved not only the outcomes for allergic rhinitis, but also its comorbid allergic conditions.


Drug Research ◽  
2017 ◽  
Vol 67 (12) ◽  
pp. 681-687 ◽  
Author(s):  
S. Ghanbarzadeh ◽  
H. Hamishehkar

AbstractAlthough chemotherapies are successful in some cases, systemic toxicity could be simultaneously observed due to the lack of drugs selectivity to cancerous tissues, leading to the failure of the chemotherapies. Furthermore, the therapeutic effects will be significantly improved if the anticancer drugs could be delivered to cancer cells with high selectivity. In recent years, there have been many advances in the field of diagnosis and treatment of cancer as a result of the development of novel materials with noticeable and often unique properties. Nanoparticles have unique biological properties, owing to their small size and large surface area-to-volume ratio, which allow them to bind, absorb, and carry compounds such as small molecule drugs, DNA, RNA, proteins, and probes with high efficiency. In the course of the last decade, Graphene and its derivatives have attracted growing interest in medicinal and pharmaceutical sciences, and many studies have focused on the potential of Graphene and its derivatives as carriers for targeted drug delivery intended for cancer diagnosis and therapies. In the present study, we will review the characteistics and application of Graphene and its different derivatives and finally discuss the opportunities, limitations, and challenges in this encouraging field.


Sign in / Sign up

Export Citation Format

Share Document